BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 24330748)

  • 1. Id4 dependent acetylation restores mutant-p53 transcriptional activity.
    Knowell AE; Patel D; Morton DJ; Sharma P; Glymph S; Chaudhary J
    Mol Cancer; 2013 Dec; 12():161. PubMed ID: 24330748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ID4 regulates transcriptional activity of wild type and mutant p53 via K373 acetylation.
    Morton DJ; Patel D; Joshi J; Hunt A; Knowell AE; Chaudhary J
    Oncotarget; 2017 Jan; 8(2):2536-2549. PubMed ID: 27911860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitor of differentiation 4 (Id4) is a potential tumor suppressor in prostate cancer.
    Carey JP; Asirvatham AJ; Galm O; Ghogomu TA; Chaudhary J
    BMC Cancer; 2009 Jun; 9():173. PubMed ID: 19500415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitor of differentiation 4 (ID4) acts as an inhibitor of ID-1, -2 and -3 and promotes basic helix loop helix (bHLH) E47 DNA binding and transcriptional activity.
    Sharma P; Chinaranagari S; Chaudhary J
    Biochimie; 2015 May; 112():139-50. PubMed ID: 25778840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1).
    Zhao Y; Lu S; Wu L; Chai G; Wang H; Chen Y; Sun J; Yu Y; Zhou W; Zheng Q; Wu M; Otterson GA; Zhu WG
    Mol Cell Biol; 2006 Apr; 26(7):2782-90. PubMed ID: 16537920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis.
    Fontemaggi G; Dell'Orso S; Trisciuoglio D; Shay T; Melucci E; Fazi F; Terrenato I; Mottolese M; Muti P; Domany E; Del Bufalo D; Strano S; Blandino G
    Nat Struct Mol Biol; 2009 Oct; 16(10):1086-93. PubMed ID: 19783986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel histone deacetylase inhibitor CG200745 induces clonogenic cell death by modulating acetylation of p53 in cancer cells.
    Oh ET; Park MT; Choi BH; Ro S; Choi EK; Jeong SY; Park HJ
    Invest New Drugs; 2012 Apr; 30(2):435-42. PubMed ID: 20978925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Id4 deficiency attenuates prostate development and promotes PIN-like lesions by regulating androgen receptor activity and expression of NKX3.1 and PTEN.
    Sharma P; Knowell AE; Chinaranagari S; Komaragiri S; Nagappan P; Patel D; Havrda MC; Chaudhary J
    Mol Cancer; 2013 Jun; 12():67. PubMed ID: 23786676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Id4 promotes senescence and sensitivity to doxorubicin-induced apoptosis in DU145 prostate cancer cells.
    Carey JP; Knowell AE; Chinaranagari S; Chaudhary J
    Anticancer Res; 2013 Oct; 33(10):4271-8. PubMed ID: 24122992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 mutant-type in human prostate cancer cells determines the sensitivity to phenethyl isothiocyanate induced growth inhibition.
    Aggarwal M; Saxena R; Asif N; Sinclair E; Tan J; Cruz I; Berry D; Kallakury B; Pham Q; Wang TTY; Chung FL
    J Exp Clin Cancer Res; 2019 Jul; 38(1):307. PubMed ID: 31307507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Restoration of DNA-binding and growth-suppressive activity of mutant forms of p53 via a PCAF-mediated acetylation pathway.
    Perez RE; Knights CD; Sahu G; Catania J; Kolukula VK; Stoler D; Graessmann A; Ogryzko V; Pishvaian M; Albanese C; Avantaggiati ML
    J Cell Physiol; 2010 Nov; 225(2):394-405. PubMed ID: 20589832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ID4 promotes AR expression and blocks tumorigenicity of PC3 prostate cancer cells.
    Komaragiri SK; Bostanthirige DH; Morton DJ; Patel D; Joshi J; Upadhyay S; Chaudhary J
    Biochem Biophys Res Commun; 2016 Sep; 478(1):60-66. PubMed ID: 27462022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EZH2 dependent H3K27me3 is involved in epigenetic silencing of ID4 in prostate cancer.
    Chinaranagari S; Sharma P; Chaudhary J
    Oncotarget; 2014 Aug; 5(16):7172-82. PubMed ID: 25115397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 Oligomerization is essential for its C-terminal lysine acetylation.
    Itahana Y; Ke H; Zhang Y
    J Biol Chem; 2009 Feb; 284(8):5158-64. PubMed ID: 19106109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The histone acetyltransferase PCAF regulates p21 transcription through stress-induced acetylation of histone H3.
    Love IM; Sekaric P; Shi D; Grossman SR; Androphy EJ
    Cell Cycle; 2012 Jul; 11(13):2458-66. PubMed ID: 22713239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chromatin remodelling protein SMAR1 inhibits p53 dependent transactivation by regulating acetyl transferase p300.
    Sinha S; Malonia SK; Mittal SP; Mathai J; Pal JK; Chattopadhyay S
    Int J Biochem Cell Biol; 2012 Jan; 44(1):46-52. PubMed ID: 22074660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intra-tumoral delivery of functional ID4 protein via PCL/maltodextrin nano-particle inhibits prostate cancer growth.
    Korang-Yeboah M; Patel D; Morton D; Sharma P; Gorantla Y; Joshi J; Nagappan P; Pallaniappan R; Chaudhary J
    Oncotarget; 2016 Oct; 7(42):68072-68085. PubMed ID: 27487149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential expression of genes induced by resveratrol in LNCaP cells: P53-mediated molecular targets.
    Narayanan BA; Narayanan NK; Re GG; Nixon DW
    Int J Cancer; 2003 Mar; 104(2):204-12. PubMed ID: 12569576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic inactivation of inhibitor of differentiation 4 (Id4) correlates with prostate cancer.
    Sharma P; Chinaranagari S; Patel D; Carey J; Chaudhary J
    Cancer Med; 2012 Oct; 1(2):176-86. PubMed ID: 23342267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The WTX tumor suppressor enhances p53 acetylation by CBP/p300.
    Kim WJ; Rivera MN; Coffman EJ; Haber DA
    Mol Cell; 2012 Mar; 45(5):587-97. PubMed ID: 22285752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.